Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

Ethylphenidate

Psychoactive Class

Stimulant

Chemical Class

Phenidate

Ethylphenidate is a synthetic stimulant of the substituted phenidate class and a close structural analog of methylphenidate (Ritalin). It emerged on research chemical markets around 2010–2011, producing traditional stimulant effects with a profile often regarded as more recreational than its parent compound. At lower doses it enhances focus and productivity, while higher doses tend toward euphoria. Notably, ethylphenidate is caustic and can cause severe nasal damage if insufflated.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~10 mg

Light10-20 mg

Moderate20-40 mg

Strong40-80 mg

Heavy80+ mg

Purity and quality can differ considerably between sources. Users report notable variation in effects from batch to batch, which may be influenced by individual tolerance, personal physiological factors, and differences in isomer composition resulting from synthesis methods.

Duration

Onset20-120 minutes

After Effects1-12 hours

Total4-10 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

The physical effects of ethylphenidate can be broken down into several components which progressively intensify proportional to dosage.

Dehydration Appetite suppressionIncreased heart rate

Cognitive

The cognitive effects of ethylphenidate can be broken down into several components which progressively intensify proportional to dosage. The general head space of ethylphenidate is described by many as one of extreme mental stimulation, increased focus, and powerful euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate dosages, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.

Thought acceleration Analysis enhancement WakefulnessMotivation enhancement

Forked from Subjective Effect Documentation by

Josie Kins September 2015.

Pharmacology

Pharmacodynamics

Ethylphenidate acts as a norepinephrine-dopamine reuptake inhibitor, binding to and partially blocking the transporter proteins that normally clear these monoamines from the synaptic cleft. Compared to methylphenidate, it shows greater selectivity for the dopamine transporter (DAT) with approximately equivalent efficacy, while displaying significantly reduced activity at the norepinephrine transporter (NET). It may also function as an inverse agonist at the dopamine transporter, inducing transporter reversal and subsequent dopamine release in a manner distinct from classical reuptake inhibition. The eudysmic ratio of ethylphenidate is superior to that of methylphenidate. All available pharmacodynamic data have been drawn from rodent studies.

Pharmacokinetics

Ethylphenidate is metabolized into methylphenidate and ritalinic acid. Small amounts of ethylphenidate can also be formed in vivo via hepatic transesterification when ethanol and methylphenidate are coingested, though the quantities produced are not considered pharmacologically significant.

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check

TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance

With sustained repeated ethylphenidate use, many effects may weaken, leading users to need larger doses to obtain similar results.

Baseline Reset

1-2 weeks

Half Tolerance

3-7 days

Cross Tolerance

Dopaminergic stimulants

Harm Potential

Addiction & Dependence

Psychological

Moderate

Ethylphenidate carries a moderate addiction risk and a high potential for abuse, and psychological dependence can develop in some users. Compulsive redosing is commonly reported. Cravings may occur after sudden cessation.

Physical

Withdrawal effects have been reported upon cessation of chronic use, though the specific nature and severity of physical dependence is not well documented due to the substance's limited research history.

Toxicity

Nasal/Mucous Membranes

Ethylphenidate crystals are particularly abrasive and caustic to mucous membranes; repeated insufflation can deteriorate nasal tissue and potentially damage the nasal septum, leading harm reduction sources to recommend against this route of administration.

Respiratory

Inhalation of ethylphenidate irritates lung tissue, resulting in phlegm production and an irritated cough.

Cardiovascular

Prolonged use causes vasoconstriction and cardiovascular strain including increased heart rate and blood pressure; occasional use at moderate doses carries less risk, though chest pain has been reported as a side effect.

Psychosis Risk

Abuse at high dosages for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Based on research into related stimulants, approximately 5–15% of users who develop stimulant psychosis may not fully recover, though antipsychotic medications can effectively resolve acute symptoms.

History & Culture

Ethylphenidate emerged on the recreational drug market around 2010-2011 and gained increasing popularity over the subsequent years. It became primarily distributed as a research chemical through online vendors, exploiting its grey-area legal status in various jurisdictions during this period. The…

Legality

International

The Commission on Narcotic Drugs' 2015 report records Decision 58/5 to include ethylphenidate in Schedule II. The UN Treaty Collection is the current official treaty-status source. This establishes international scheduling, not a verified domestic criminal/medical conduct outcome for any core jurisdiction.

By Country

Illegal20

United StatesIllegal

AustraliaIllegal (analog/blanket ban)

AustriaIllegal

BrazilIllegal

CanadaIllegal

ChinaIllegal

DenmarkIllegal

FinlandIllegal

GermanyIllegal

JapanIllegal

JerseyIllegal

NetherlandsIllegal

NorwayIllegal

PhilippinesIllegal

PolandIllegal

SingaporeIllegal

SwedenIllegal

SwitzerlandIllegal

UkraineIllegal

United KingdomIllegal

Controlled / restricted1

ColombiaRestricted

Prescription1

IndonesiaPrescription only

References

Citations

Article Status

Step 1 · Automated synthesis
An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest 24 Jan

Times are UTCNewest first

24 January 2026

23:32
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
23:25
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
23:20
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
23:15
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
22:57
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
22:42
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
22:21
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Ethylphenidate article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.